Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 154
- Registration Number
- NCT02561130
- Locations
- 🇨🇦
Health Science Centre, Winnipeg, Manitoba, Canada
🇨🇦McMaster University, Hamilton, Ontario, Canada
🇨🇦LMC, Toronto, Ontario, Canada
Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin
- Conditions
- Physical Activity
- Interventions
- Drug: PlaceboDrug: MetforminDietary Supplement: Carbohydrate BeverageDietary Supplement: Protein Beverage
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Colorado State University
- Target Recruit Count
- 56
- Registration Number
- NCT02552355
- Locations
- 🇺🇸
Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 650
- Registration Number
- NCT02551874
- Locations
- 🇸🇪
Research Site, Uddevalla, Sweden
The Effect of Metformin on Composition of Human Gut Bacteria
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Oluf Borbye Pedersen
- Target Recruit Count
- 26
- Registration Number
- NCT02546050
- Locations
- 🇩🇰
The Novo Nordisk Foundation Center of Basic Metabolic Research, Section for Metabolic Genetics, University of Copenhagen, Copenhagen, Copenhagen Ø, Denmark
The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT02535975
- Locations
- 🇰🇷
Endocrinology, Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
- Conditions
- GLP-1；Metformin；Telomere-telomerase System；Par-4
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02535299
- Locations
- 🇨🇳
Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, China
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT02532855
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT02531308
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes
- Conditions
- Type 2 DiabetesInsulin Sensitivity
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT02526615
- Locations
- 🇫🇮
Turku PET Centre, Turku, Finland
🇫🇮Turku university hospital, PET center, Turku, Finland
🇫🇮Turku PET Centre (Turku University Hospital), Turku, Finland
The Effect of Gelesis100 on the Pharmacokinetics of Metformin
- Conditions
- Healthy Overweight Obese
- Interventions
- Device: Gelesis100Drug: Metformin
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02524821
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.